PRIMENA OFF-LABEL LEKOVA U PEDIJATRIJSKOJ POPULACIJI

Sara Radojević, Dušanka Krajnović

UNIVERZITET U BEOGRADU – FARMACEUTSKI FAKULTET, BEOGRAD, SRBIJA

Sažetak: ZNAČAJ PROBLEMA. Savremena upotreba lekova u terapiji oboljenja dece i novorođenčadi se sve više bazira na off-label primeni lekova. Off-label primena lekova podrazumeva primenu lekova u većoj ili manjoj dozi, primena za indikacije koje nisu opisane u sažetu karakteristika o leku, primena kod dece van opsega godina koji je definisan dozvolom, primena alternativnim putevima primene i primena lekova u indikacijama kada je kontraindikovan prema dozvoli za dati lek. Primena off-label lekova je uglavnom vezana za prevenciju, dijagnostiku ili terapijske mere koje su u skladu sa relevantnim legislativom sa primarnim ciljem da poboljšaju, održave ili popravite zdravstveno stanje. Masovnoj primeni ovih lekova doprineo je nedostatak adekvatnih formulacija za pedijatrijsku populaciju, nepostojanje odgovarajućih terapijskih paralela za terapiju oboljenja dece i mali broj kliničkih ispitivanja koja uključuju pedijatrijsku populaciju. U protekle dve decenije, mnoge zakonodavne i regulatore inicijative su preduzete što bi poboljšalo primenu lekova kod dece. Međutim, i dalje se deci potrebljuju lekove koji nisu registrovani za upotrebu u pedijatrijskoj populaciji. Kefikasni, kvalitetni bezbedni za primenu.

Off-label primena lekova podrazumeva kolaboraciju zdravstvenih radnika i drugih stručnjaka u cilju obezbeđivanja lekova za dece koji su dokazano efikasni, kvalitetni bezbedni za primenu.

Off-label lekovi su lekovi koji nisu registrovani za upotrebu u pedijatrijskoj populaciji i predstavljaju jednu od najviše propisivanih lekova u ovoj studiji.

Komentar: Off-label lekovi su uvek predmet istraživanja koje predstavljaju veliku kliničku bitnost.

ZAKLJUČAK: Analizom literature, prevalenca propisivanja off-label lekova u pedijatrijskoj populaciji je evidentna i veoma rasprostranjena sa širokim varijacijama zavisno od zemlje i leka.

Ključne reči: off-label lekovi, opravdanost primene off-label lekova, pedijatrijska medicina, lekovi u pedijatriji.
USE OF OFF-LABEL MEDICINES IN PEDIATRIC POPULATION

Sara Radojević, Dušanka Krajnović

UNIVERSITY OF BELGRADE - FACULTY OF PHARMACEUTICALS, BELGRADE, SERBIA

Abstract: Modern use of drugs in the treatment of diseases of children and newborns is increasingly based on off-label use of drugs. The lack of adequate formulations for the pediatric population, the lack of appropriate therapeutic parallels for the treatment of children's diseases and the small number of clinical trials involving the pediatric population have contributed to the mass use of these drugs. The use of these drugs implies extrapolation of doses and indications registered for adults to children, although it is known that the pharmacodynamics and pharmacokinetics of children and adults differ significantly. In the past two decades, many legislative and regulatory initiatives have been taken around the world to improve the use of drugs in children. However, children are still prescribed off-label and unlicensed drugs.

The aim of this study was to present a review of the literature in which off-label and unlicensed use in the pediatric population was investigated. Literature was searched through the Google Scholar and Pub Med search engines and using the keywords off label drug, pediatric medicine, use in pediatrics, in the period from May to August 2019. Selected and presented in this article are studies published in the period from 1996 to 2015, which as a subject of research had the use of off-label and unlicensed drugs in the pediatric population. Medicines prescribed for children should be registered for use in the pediatric population and used in accordance with approved indications for children, whenever possible. It is necessary to take measures for more rational use of medicines in pediatrics, which include the collaboration of health workers in order to provide medicines for children that are proven to be effective, high quality and safe to use.

INTRODUCTION

The use of a medicinal product in accordance with the marketing authorization, which defines the formulation, dosage, age, and issued by the relevant regulatory body, is called the use of the medicinal product in accordance with the on-label marketing authorization. The purpose of authorizing a medicinal product is to ensure that the medicinal product is tested for its efficacy, safety and quality. When the drug is prescribed outside the examined indications, the therapy may be less safe, effective and reliable, because it is based exclusively on assumptions and extrapolation. The justification for prescribing these drugs, especially in the pediatric population, due to the large differences between children and adults, even between children of different ages, in terms of pharmacodynamic and pharmacokinetic responses to the drug, is being examined.

Recently, the use of a drug that does not comply with the approved guidelines related to the indication, age, dosage regime or route of administration is becoming more common. Off-label use of drugs includes the use of drugs in higher or lower doses, use for indications not described in the summary of product characteristics, use in children outside the range of years defined by the license, use of alternative routes of administration and use of drugs in indications when contraindicated for a given drug. The use of off-label drugs is mainly related to prevention, diagnosis or therapeutic measures that are in accordance with the relevant legislation, with the primary goal of improving or improving the health condition.

Off-label use of drugs should be distinguished from the use of drugs without a license (off-license). Unlicensed use of drugs is considered to be the use of a drug that is not registered in the Republic of Serbia, but is in other countries, or that is registered, but it should be translated into another formulation or drug that is not registered (eg. for the treatment of rare diseases). Unregistered medicines are medicines that have not been approved by the regulatory body for marketing. Off-label use is considered to be the use of a drug in a way different from the manner described in the marketing authorization: use of the drug for the treatment of an indication not listed in the
UVOD

 Primena leka koja je u skladu sa dozvolom za lek kojom je definisana formulacija, doziranje, godine starosti i koju izdaje relevantno regulatomo telo, naziva se primena leka u skladu sa dozvolom za lek (on-label). Svrha izdavanja dozvale za lek je da se obezbedi da se lekovi ispitaju u pogledu njihove efikasnosti, bezbednosti i kvaliteta. Kada se lek propisuje van ispitanih indikacija, terapija može da bude manje bezbedna, efikasna i pouzdana jer se temelji isključivo na pretpostavkama i ekstrapolaciji. Ispituje se opravdanost propisivanja ovih lekova, naročito u pedijatrijskoj populaciji, zbog postojanja velikih razlika između dece i odraslih, čak i između dece različitih uzrasta, u pogledu farmakokinetskih i farmakokinetičkih odgovora na lek.

U poslednje vreme, primena leka koja nije u skladu sa odobrenim smernicama vezanim za indikaciju, starosnu doz, režim doziranja ili stojanje velikih razlika u vezi sa većoj dozi od navedene u sažetku karakteristika grupe van dozvoljenog opsega, korišćenje leka u većoj ili manjoj dozi, primena alternativnim putevima primene i primena lekova u indikacijama kada je kontraindikovan prema dozvoli za dati lek.

Savremena upotreba lekova u terapiji oboljenja dece i novorođenčadi se sve više bazira na primeni lekova off-label zbog nedostatka adekvatnih formulacija za pedijatrijsku populaciju, nepostojanje odgovarajućih terapijskih paraleta za terapiju oboljenja dece i gotovo nepostojanje kliničkih ispitanja koja uključuju pedijatrijsku populaciju [1,2,3,4]. Katastrofa talidomida (fokomelija kod novorođenčadi) i efekat upotrebe hloramfenikola kod dece (siva beba sindrom) pokrenuo je proces ispitivanja i registracije lekova [5]. Glavni cilj registracije lekova je da se obezbedi da lek bude kvalitet, bezbedan i efikasan. Nažalost, veliki broj lekova za decu nema dozvolu za stavljanje u promet ili odobrenje za promet [6]. Ovo sugerisao da za mnoge lekove koji se primenjuju kod dece nedostaju dokazi izvedeni iz farmakokinetike, adekvatnog doziranja ili studija vezanih za formulacije [7,8]. Fokusiranje na druge faktore koji utiču na farmakokinetiku i farmakodinamiku doziranja lekova dobijalo je maša pažnje tokom razvoja lekova za decu. Zbog toga su se koristili mnogi lekovi van svojih licenciranih preporuka, što je uobičajeno poznat kao off-label propisivanje, što je postao sve češći trend u propisivanju kod dece. Propisivanje van upotrebne dozvole kod dece je rasprostranjeno uglavnom u sistemskim primenjenim lekovima, ali i lokalno primenjenim lekovima [9].

Najčešći razlog za primenu neregistrovanih lekova su modifikacije registrovanih lekova (mravljenje tablete da bi se formirala suspenzija), lekovi koji su registrovani za primenu kod odraslih, ali za formulaciju za primenu u pedijatriji je potrebna posebna dozvolu za lek (lek za odrasle se primeni u manjoj dozi za decu), novi lekovi koji zahtevaju specijalnu dozvolu proizvođača (npr. injekcija kofeina koja se primenjuje u slučaju apneje zbog nezrelosti pluća). Upotreba lekova van upotrebne dozvole podrazumeva primenu lekova u većoj ili manjoj dozi, primenu alternativnim putevima primene i primenu lekova u indikacijama kada je kontraindikovan prema dozvoli za dati lek.

Vol. 46 (2021) br. 2

Originalni rad

www.tmg.org.rs
summary of product characteristics, use of the drug in the age group outside the permitted range, use of the drug doses of the drug characteristics listed in the summary.

The most common reasons for the use of unregistered drugs are modifications of registered drugs (crushing the tablet to form a suspension), drugs that are registered for use in adults, but the formulation for use in pediatrics requires a special drug permit (adult drug is used in minor doses for children), new drugs that require special permission from the manufacturer (eg. caffeine injection used in case of apnea due to lung immaturity). Use of drugs outside the marketing authorization includes the use of drugs in higher or lower doses, use for indications not described in the summary of product characteristics, use in children outside the age range defined by the license, use of alternative routes of administration and use of drugs in indications when contraindicated allow for a given drug.

Modern use of drugs in the treatment of diseases of children and newborns is increasingly based on the use of off-label drugs due to lack of adequate formulations for the pediatric population, lack of appropriate therapeutic parallels for the treatment of children and almost no clinical trials involving the pediatric population [1-4].

The thalidomide catastrophe (phocomelia in newborns) and the effect of the use of chloramphenicol in children (gray baby syndrome) initiated the process of testing and registration of drugs [5]. The main goal of drug registration is to ensure that the drug is quality, safe and effective. Unfortunately, large number of medicines for children do not have a marketing authorization or marketing authorization [6]. This suggests that for many drugs used in children, evidence derived from pharmacokinetics, adequate dosing, or formulation-related studies is lacking [7,8]. Focusing on other factors influencing the pharmacokinetics and pharmacodynamics of drug dosing has received little attention during drug development in children. As a result, many drugs have been used outside of their licensed recommendations, commonly known as off-label prescribing, which has become an increasingly common prescribing trend in children. Over-the-counter prescribing for children is widespread mainly in systemically administered drugs, but also in locally applied drugs [9].

Several factors leading to off-label prescribing in children have been identified in the past. Subsequently, legislative, regulatory, governmental, and professional initiatives were introduced and implemented globally to obtain better data on the effects of drugs on children and consequently to instruct health professionals to use quality drugs that are effective for children and do not cause harm when used. Initiatives to improve drug use in children were first implemented in the United States from 1994 to early 2000. [10-13]. Almost a decade later, other countries (European Union, Canada, Australia, Japan, China and Korea) as well as international institutions (World Health Organization and the International Council for the Harmonization of Technical Requirements for Pharmaceutical Medicines for Human Use) have joined [14]. Data from the literature show that most initiatives taken in the past have been aimed at encouraging increased research on the use of drugs in children, in order to improve the registration process and enable the safe use of drugs in the pediatric population.

However, despite numerous global initiatives, the number of clinical trials conducted in children is still insufficient, ie. the use of drugs in children is rarely based on evidence from clinical trials [15].

The aim of this study is to provide an overview of the global trend and prevalence of prescribing off-label drugs from 1996 to 2016, and to suggest future directions related to studies related to off-label prescribing in children.

METHODOLOGY

Data collection was performed by electronic search of the PubMed index database and Google Scholar. The literature search and selection protocol has been defined using the PRIZMA method [16]. The corresponding flow diagram is graphically shown in Figure 1. The search was performed in the period from May to August 2019. Selected and presented in the paper are studies published in the period from 1996 to 2015. Searched keywords are: off label drug, pediatric medicine, use in pediatrics. Original research was included which provided data on the extent of use of off-label and unlicensed drugs in the pediatric population as well as one systematic review.

Criteria for inclusion were: 1) published texts in full text in the period from January 1996
primjenjene globalno da bi se dobili što bolji podaci o dejstvu lekova na decu i posledično o upućivanju zdravstvenih radnika da koriste kvalitetne lekove koji su delotvorni za decu i ne izazivaju štetnost pri likom primene. Inicijative preduzete za poboljšanje upotrebe lekova kod dece prvo su spovedene u Sjedinjenim Američkim Državama (SAD) od 1994. do početka 2000. godine [10-13]. Skoro deceniju kasnije uključile su se i druge zemlje (Evropska Unija, Kanada, Australija, Japan, Kina i Koreja) kao i međunarodne institucije (Svetska zdravstvena organizacija i Međunarodni savet za harmonizaciju tehničkih zahteva za farmaceutske lekove za humanu upotrebu) [14].

Podaci iz literature pokazuju da je većina inicijativa preduzetih u prošlosti bila usmerena na podsticanje povećanja istraživanja za upotrebu lekova kod dece, kako bi se poboljšao proces registracije i omogućila bezbedna primena lekova u dečjoj populaciji. Međutim, uprkos brojnim preduzetim globalnim inicijativama, broj sprovedenih kliničkih ispitivanja kod dece još uvijek nedovoljan, odnosno upotreba lekova kod dece je retko zasnovana na dokazima iz kliničkih ispitivanja [15].

Gilj ove studije je da pruži pregled svetskog trenda i prevalence propisivanja off-label lekova od 1996. do 2016. godine, i sugestija o budućim pravcima vezanim za studije vezane za off-label propisivanje kod dece.

**MATERIJAL I METODE**

Prikupljanje podataka izvršeno je elektronskom pretragom indeksne baze PubMed i Google Scholar. Protokol pretraživanja i izbora literature je definisan primenom PRIZMA metode [16]. Odgovarajući dijagram toka je grafički prikazan na Slici 1. Pretraga je obavljena u periodu od maja do avgusta 2019. godine. Odabrane studije koje su prikazane u radu objavljene su u periodu od 1996. do 2015. godine. Pretraživane ključne reči su: off label drug, pediatric medicine, use in pediatrics. Uključene su originalna istraživanja koje su dale podatke o obimu primene off-label i unlicensed lekova u pedijatrijskoj populaciji kao i jedan sistematski pregled.

Kriterijumi za uključivanje bili su: 1) objavljeni radovi u celom tekstu (in extenso) u periodu od januara 1996. do decembra 2016. godine 2) članci na srpskom i engleskom jeziku 3) studije koje prikazuju podatke o rezultatima prevalencii propisivanja lekova van upotrebne dozvole kod dece; 4) off label primena kardioloških, respiratornih, antialiemijskih, onkoloških, analgetskih lekova i antibiotika. Kriterijumi za isključenje bili su: 1) beleške i konferencije 2) off label primena drugih terapijskih grupa lekova.

Naslov i sažetak članaka su pomno ispitani da se utvrdi mogu li se uključiti studije u ovaj pregled. Sledeće informacije su izvučene iz prihvatljivih studija: 1) identifikacija studije 2) detalji studije (dizajn studija, postavka, period studija, metoda) 3) definisanje off label primene lekova 4) reference izvora 5) kvantifikovanje ishoda 6) rezultati.

---

www.tmg.org.rs
to December 2016; 2) articles in Serbian and English; 3) studies showing data on the results of the prevalence of prescribing drugs outside the use permit for children; 4) off label use of cardiac, respiratory, antiallergic, oncological, analgesic drugs and antibiotics

Exclusion criteria were: 1) notes and conferences; 2) off label use of other therapeutic groups of drugs. The title and summary of the articles have been carefully examined to determine the inclusion of the study in this review. The following information was extracted from the eligible studies: 1) study identification; 2) study details (study design, setting, study period, method); 3) defining off-label drug administration; 4) source references; 5) quantification of outcomes; 6) results

RESULTS AND DISCUSSION

During the research, 101 studies were identified, of which 7 were presented in this article, with the aim of presenting off-label use of drugs in different therapeutic groups: cardiac, respiratory, antiallergic drugs, antibiotics, oncology drugs and analgesics.

In a study conducted at the Department of Pediatric Cardiology, 544 patients participated in the University Children's Hospital in Belgrade and included 2,037 prescriptions, with 102 different drugs, of which 41% were registered drugs, 11% unregistered and 47% prescribed drugs. off-label. Drugs are prescribed off-label: due to age 21% and due to a different dose 26%. The largest number of unregistered and off-label drugs (72%) is prescribed to children aged between 2-11 years.

Katopil is the only registered ACE inhibitor for use in the pediatric population and is one of the most prescribed drugs in this study, with one-third of prescriptions being prescribed off-label in relation to the dose of katopil [17].

In a national cohort study conducted in Italy, in the period 2002-2006, medical records of children under 14 years of age were analyzed, and the degree of prescribing drugs belonging to the ATC code R03 - β mimetics, inhaled glucocorticoids, inhaled anticholinergics, combined formulations, antiallergic drugs, xanthines and leukotriene receptor antagonists. 90% of R03 prescriptions included 11 active substances or combinations. Inhaled glucocorticoids are the most prescribed off-label, with 19% in terms of age and 56% in terms of indications for use. The largest number of off-label drugs was in children younger than 2 years [18].

In the cohort study, conducted in the Netherlands, the largest number of prescribed drugs - off-label and unregistered - was also the largest in the group of children aged 1 month to
REZULTATI I DISKUSIJA

U toku istraživanja identifikovana je 101 studija, od kojih je u ovom radu prikazano 7 najreprezentativnijih sa ciljem prikazivanja off-label primene lekova u različitim terapijskim grupama: kardiološki, respiratorni, antialergijski lekovi, antibiotici, onkološki lekovi i analgetici.

U istraživanju sprovedenom na odeljenju Pedijatrijske kardiologije na Univerzitetskoj dečjoj bolnici u Beogradu učestvovalo je 544 pacijenta i obuhvaćeno je 2037 recepata, sa 102 različita leka, od kojih je 41% bilo registrovanih lekova, 11% neregistrovanih i 47% lekova propisanih koji su primenjeni off-label. Lekovi su off-label propisivani: zbog uzrasta 21% i zbog drugačije doze 26%. Najveći broj neregistrovanih i off-label lekova (72%) je propisivano deči uzrasta između 2-11 godina. Najveći broj neregistrovanih i off-label lekova (72%) je propisivano deči uzrasta između 2-11 godina. Kaptopril je jedini registrovan ACE inhibitor za upotrebu u pedijatrijskoj populaciji i jedan je od najviše propisanih lekova u ovoj studiji, s tim što je jedna trećina recepata bila propisana off-label, a u vezi sa dozom katopila [17].

U nacionalnoj kohortnoj studiji sprovedenoj u Italiji, u periodu 2002.-2006. godine analizirani su medicinski kartoni dece mlađe od 14 godina i obuhvatao je 2037 recepata, sa 102 različita leka, od kojih je 41% bilo registrovanih lekova, 11% neregistrovanih i 47% lekova propisanih koji su primenjeni off-label. Lekovi su off-label propisivani: zbog uzrasta 21% i zbog drugačije doze 26%. Najveći broj neregistrovanih i off-label lekova (72%) je propisivano deči uzrasta između 2-11 godina. Kaptopril je jedini registrovan ACE inhibitor za upotrebu u pedijatrijskoj populaciji i jedan je od najviše propisanih lekova u ovoj studiji, s tim što je jedna trećina recepata bila propisana off-label, a u vezi sa dozom katopila [17].

U nacionalnoj kohortnoj studiji sprovedenoj u Italiji, u periodu 2002.-2006. godine analizirani su medicinski kartoni dece mlađe od 14 godina i obuhvatao je 2037 recepata, sa 102 različita leka, od kojih je 41% bilo registrovanih lekova, 11% neregistrovanih i 47% lekova propisanih koji su primenjeni off-label. Lekovi su off-label propisivani: zbog uzrasta 21% i zbog drugačije doze 26%. Najveći broj neregistrovanih i off-label lekova (72%) je propisivano deči uzrasta između 2-11 godina. Kaptopril je jedini registrovan ACE inhibitor za upotrebu u pedijatrijskoj populaciji i jedan je od najviše propisanih lekova u ovoj studiji, s tim što je jedna trećina recepata bila propisana off-label, a u vezi sa dozom katopila [17].
2 years. The one-year cumulative risk of off-label and unregistered drugs is 45%, among children with at least one prescription for a respiratory drug [19].

In a prospective study, which lasted from February to March 2000, at the Children's Clinic in Great Britain, in the intensive care and acute care wards, analgesics used in children were classified into those used in accordance with the marketing authorization and those are applied off-label, in accordance with the valid drug registries in the UK. The study included 715 prescriptions, of which 67% were licensed drugs, prescribed in accordance with the summary of product characteristics, and 33% were licensed drugs, but prescribed outside the use permit. Diclofenac, pethidine and morphine are mostly prescribed off-label, while drugs are most often prescribed off-label, in terms of dose. The high percentage of off-label use of this drug, shown in this study, is explained by the fact that diclofenac is not approved for pain therapy in children, but that it has been shown to be effective in adults intra- and postoperatively [20].

The Morais-Almeida M study (2013) showed that the most prescribed off-label drugs were nasal corticosteroids, 76% of the total number of prescription drugs [21], while 22% were off-label antihistamines. In other studies, off-label administration of antihistamines varied between 4.5 - 43%. Cetirizine, levocetirizine and loratadine have been most studied in terms of long-term safety when used in the pediatric population. Despite pharmacokinetic studies conducted for next-generation antihistamines, long-term safety studies in children are lacking [22].

A study conducted in three European countries, Italy, Great Britain and Greece, evaluated the off-label use of antibiotics, as the most frequently prescribed drugs for children. The number of prescribed drugs with an unregistered dose was high in all three countries in the neonatology departments, but the number was significantly higher in Italy compared to the United Kingdom. Antibiotics that are most often prescribed outside the recommended dose are aminoglycosides, specifically amikacin and gentamicin. The most common clinical indication for use outside the recommended range is suspected or confirmed diagnosis of sepsis, although significant use of drugs outside the recommended doses in medical prophylaxis was more common in Italy and Greece, compared to the United Kingdom. The most frequently prescribed antibiotics prescribed outside the registered indication are fluoroquinolones in Great Britain and ampicillin and gentamicin in Italy and Greece, while the most common indications were suspected sepsis or diagnosed sepsis.

In the pediatric ward, antibiotics most commonly prescribed outside the registered dose are amoxicillin clavulanate in Italy, cefuroxime in Greece, and gentamicin in the United Kingdom. Doses were higher than recommended in Italy and Greece and lower than recommended in the UK. The most common dosages outside the registered recommendations were indications - sepsis, lower respiratory tract infections and surgical prophylaxis in all three countries, regardless of prevalence. Off-label in terms of dose was most common in the group of children aged 28 days - 23 months [23].

The use of anticancer drugs is precisely described in the drug authorization in terms of the type or subtype of the tumor and the length of treatment. Prescribing anticancer drugs is believed to be often prescribed outside the use permit, while a small number of studies have been conducted, in order to obtain a realistic state. Prospective studies, conducted between 1990 and 2002, indicated a proportion of off-label drug use in children and adults. Most off-label drugs were for palliative care of patients, some were associated with a better clinical effect and in the treatment of specific tumors, they were part of standard therapy [24].
doze. Visok procenat off-label primene ovog leka, pokazan u ovoj studiji, objašnjava se činjenicom da diklofenak nije odobren za terapiju bola kod dece, ali da se kod odraslih intra- i postoperativno pokazao kao efikasan [20].

U studiji Silva D (2013) pokazano je da su najviše propisivani off-label lekovi nazalni kortikosteroidi, 76% od ukupnog broja lekova propisanih na recepat [21], dok je 22% činila off-label primena antihistaminika. U ostalim studijama, off-label primena antihistaminika je varirala između 4,5-43%. Cetirizin, levocetirizin i loratadin su najviše ispitivani u pogledu dugotrajne bezbednosti kod primene u pedijatrijskoj populaciji. Upkrkos farmakokinetičkim studijama sprovedenim za antihistaminike nove generacije, nedostaju studije bezbednosti dugotrajne primene kod dece [22].

U istraživanju sprovedenom u tri evropske zemlje, Italiji, Velikoj Britaniji i Grčkoj evaluirana je off-label primena antibiotika, kao najfrekventnije propisivanih lekova dece. Broj propisanih lekova sa neregistracijom dozom bio je visok u sve tri zemlje na neonatološkim odeljenjima, ali je broj bio značajno veći u Italiji u odnosu na Veliku Britaniju. Antibiotici koji su najčešće propisivani van preporučenih doza su amoksicilin-klavulanat u Italiji, cefuroksim u Grčkoj i gentamicin u Velikoj Britaniji. Doze su bile više od preporučenih u Italiji i Grčkoj i manje od preporučenih u Velikoj Britaniji. Najčešće doziranje van registrovanih doza su bile indukcije – septa, infekcije donjih respiratorskih puteva i hiruška profilakska u sve tri zemlje, bez razlike u prevalencijama. Off-label u smislu doze je bila najzastupljenija u grupi dece starosti 28 dana – 23 meseca [23].

Upotreba antičancerkskih lekova je precizno opisana u dozvoli za lek u pogledu tipa ili podtipa tumora i dužine tretmana. Za propisivanje antičancerkskih lekova se veruje da se često propisuju van upotrebne dozvole, dok je malo broj studija sproveden, kako bi se dobila realno stanje. Prospektivne studije, sprovedene između 1990. i 2002. godine, ukazale su na proporciju off-label primene lekova kod dece i kod odraslih. Većina off-label lekova je za bila za položivnu negu pacijenata, neki su bili u vezi sa boljim kliničkim efektom i u terapiji specifičnih tumora, bili su deo standardne terapije [24].

| Autori/ časopis/ godina | Studija | Cilj | Metoda | Rezultati |
|--------------------------|---------|-----|--------|----------|
| Bajcetic et al./Eur J Clin Pharmacol/ 2005 | Off label i neregistrovani lekovi u pedijatrijskoj kardiologiji | Obim i priroda propisivanja lekova off label u pedijatrijskoj kardiologiji, kod hospitalizovanih pacijenata | Prospektivna studija; kartoni pacijenata | Problem off label i neregistrovanih lekova je u skladu sa nedostatkom adekvatnih formulacija na globalnom nivou |
| Jong, Eland et al./ Eur Respir J/2004 | Neregistrovani i off label respiratorni lekovi koji se propisuju pedijatrijskoj populaciji | Neregistrovani i off label respiratorni lekovi koji se propisuju deci, Holandija | Kohortna, nacionalna studija; podaci su prikupljeni iz kompјuterizovane baze medicinskih kartona dece | Veći procenat respiratornih lekova koji se propisuju deci su neregistrovani ili registrovani ali propisani off label |
Table 1: Tabelar view of studies presented in this article

| Authors/ Article/ Year | Study                                                                 | Aim of the study                                                                 | Methods                                                                 | Results                                                                 |
|------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Bajcetic et al./ Eur J Clin Pharmacol/ 2005 | Off-label and unregistered drugs in pediatric cardiology | Scope and nature of prescribing off-label drugs in pediatric cardiology, in hospitalized patients | Prospective study; patient records                                           | The problem of off-label and unregistered drugs is in line with the lack of adequate formulations globally |
| Jong, Elaad et al./ Eur Respir J/2004 | Unregistered and off-label resorption drugs prescribed to the pediatric population | Unregistered and off-label respiratory drugs prescribed to children, the Netherlands | Cohort, national study; data were collected from a computerized database of children's medical records | A large percentage of respiratory drugs prescribed to children are unregistered or registered but prescribed off label |
| Baiardi et al./ Acta Pediatrica/ 2009 | Use of the drug in accordance with the marketing authorization and off-label use of respiratory drugs in the pediatric population in Italy | To determine the degree of prescription of respiratory drugs (ATC code: R03) in Italy and to assess the extent of use of off-label drugs, in relation to the dose or indication | Cohort study                                                          | There is a need to conduct quantitative studies, with the aim of increasing current knowledge about registered medicines and to review the registration process and regulatory procedures in order to reduce off-label use of medicines |
| Conroy et al /Pediatric Anaesthesia/ 2001 | Use of off label and unregistered analgesics in the management of pain therapy in pediatrics | Document the incidence and nature of the use of unregistered and off-label analgesics in children | Prospective study; a questionnaire was used as a tool | 67% of drugs were registered; 33% is registered, but the application is off-label; the study did not identify the use of unregistered drugs |
| Silva et al./ WAO Journal/ 2014 | Prescribing off-label drugs in the treatment of allergic diseases in children | A review of the literature aimed at describing and discussing the off-label use of drugs in the therapy and control of allergic drugs in children | Review article                                                                 | There is a need for a new proposal to highlight the priority for pediatric clinical research, which could meet all the needs of the pediatric population, especially in the field of allergies and respiratory diseases. |
| Porto et al./ Eur J Clin Pharmacol/ 2010 | Use of antibiotics off-label in three European countries in children | The aim was to evaluate off-label antibiotic use in three European countries - the UK, Italy and Greece | Antibiotic prescriptions were evaluated for all hospitalized patients in the neonatal intensive care unit: 2 hospitals in the UK, one hospital in Italy and one hospital in Greece | Off-label drug use is usually dose- or indication-related, rarely for years. the only antibiotics identified that have been used off the label, and related to age are: meropenem for neonatal and quinolones and linezolid for older children, which is a priority for future studies |
| Leveque /Lancet Oncol/ 2008 | Off-label use of anticancer drugs | The scope of off-label prescribing of oncology drugs | A review of prospective studies in the period 1990-2002 | Percentage of off-label drug use in children and adults 6-33.2% |
| Autori et al. / Acta Pediatrica / 2009 | Primena leka u skladu sa dozvolom za lek i off label primena respiratornih lekova u pedijatrijskoj populaciji u Italiji | Da se odredi stepen propisivanja respiratornih lekova (ATC sifra: R03) u Italiji i da se proceni obim primene off label lekova, a vezano za dozu ili indikaciju | Kohortna studija | Postoji potreba za sprovođenjem kliničkih studija, sa ciljem povećanja trenutnog znanja o registrovanim lekovima i da izvrši revizija procesa registrovanja i regulativnih procedura kako bi se smanjila off label upotreba lekova |
| Conroy et al. / Peadiatric Anaesthesia / 2001 | Upotreba off label i neregistrovanih analgetika u menadžmentu terapije bola u pedijatriji | Dokumentovati incidencu i prirodu upotrebe neregistrovanih i off label analgetika kod dece | Prospektivna studija; kao alat je korišćen upitnik | Da se odredi stepen propisivanja respiratornih lekova (ATC sifra: R03) u Italiji i da se proceni obim primene off label lekova, a vezano za dozu ili indikaciju |
| Silva et al. / WAO Journal / 2014 | Propisivanje off label lekova u terapiji alergijskih bolesti kod dece | Pregled literature koji je za cilj imao da opiše i prodiskutuje off label upotrebu lekova u terapiji i kontroli alergijskih lekova kod dece | Pregledni rad | Da se odredi stepen propisivanja respiratornih lekova (ATC sifra: R03) u Italiji i da se proceni obim primene off label lekova, a vezano za dozu ili indikaciju |
| Porto et al. / Eur J Clin Pharmacol / 2010 | Upotreba antibiotika off label u tri evropske zemlje kod dece | Cilj je bio da se evahira off label upotreba antibiotika u tri evropske zemlje - Velika Britanija, Italija i Grčka | Recepti za antibiotike su evahirani za sve hospitalizovane pacijente u neonatološkom odeljenju intenzivne nege: 2 bolnice u Velikoj Britaniji, jedne bolnice u Italiji i jedne bolnice u Grčkoj | Da se odredi stepen propisivanja respiratornih lekova (ATC sifra: R03) u Italiji i da se proceni obim primene off label lekova, a vezano za dozu ili indikaciju |
| Leveque / Lancet Oncol / 2008 | Off label primena onkoloških lekova | Obim off label propisivanja onkoloških lekova | Pregled prospektivnih studija u periodu od 1990-2002 | Da se odredi stepen propisivanja respiratornih lekova (ATC sifra: R03) u Italiji i da se proceni obim primene off label lekova, a vezano za dozu ili indikaciju |

**ZAKLJUČAK**

Analizom literature, prevalenca propisivanja off-label i neregistrovanih lekova u pedijatrijskoj populaciji je evidentna i veoma rasprostranjena sa širokim varijacijama zavisno od zemlje i leka u opsegu od 19% do 76% u proseku oko 30 do 40%. Lekovi propisani za decu treba da budu registrovani za upotrebu u pedijatrijskoj populaciji i upotrebljeni u skladu sa odobrenim indikacijama za decu, kad god je to moguće. Iako postoje indikacije u kojima upotreba off-label i neregistrovanih lekova ima više koristi od rizika, koji primena tog leka predstavlja, to dovodi do sve veće primene ovih lekova i kada takva upotreba nije opravdana, odnosno može biti manje efikasna ili štetna. Nedostatak indikacija za primenu kod dece, u odnosu na dozu ili neadekvatna formulacija za pedijatrijsku populaciju može da spreči decu od dobijanja efikasne terapije i može dovesti do grešaka u putevima primene datog leka. Porast prevalence off-label primene lekova sugeriše da zakonodavne, regulatorne inicijative nisu dovoljne za poboljšanje upotrebe lekova kod dece. Aspekti ponašanja i znanja koji se odnose na off-label propisivanje kao i napori na integriranju dokaza u praksi takođe mora biti ocenjena i konsolidovana kao deo o zajedničkim naporima da se smanje propusti u propisivanju za decu. Potrebno je preduzeti mere za racionalniju upotrebu lekova u pedijatriji koje podrazumevaju kolaboraciju zdravstvenih radnika u cilju obezbeđivanja lekova za decu koji su dokazano efikasni, kvalitetni bezbedni za primenu.
CONCLUSION

According to the analysis of the literature, the prevalence of prescribing off-label and unregistered drugs in the pediatric population is evident and very widespread in the past in intensive care units.

Medicines prescribed for children should be registered for use in the pediatric population and used in accordance with approved indications for children, whenever possible. Although there are indications that the use of off-label and unregistered drugs has more benefits than the risk that the use of that drug poses, this leads to an increasing use of these drugs even when such use is not justified, ie. it may be less effective or harmful.

The lack of indications for use in children, in relation to the dose or inadequate formulation for the pediatric population may prevent children from receiving effective therapy or may lead to errors in the routes of administration of the drug.

The increase in the prevalence of off-label drug use suggests that legislative, regulatory initiatives are not sufficient to improve drug use in children. Aspects of behavior and knowledge related to off-label prescribing as well as efforts to integrate evidence into practice must also be assessed and consolidated as part of a joint effort to reduce prescribing gaps for children.

It is necessary to take measures for a more rational use of medicines in pediatrics, which include the collaboration of health workers in order to provide medicines for children that are proven to be effective, high quality and safe to use.

REFERENCES

1. Goločorbin-Kon S. i dr. Lekovi u prometu 2014. Novi Sad:OrtoMedics
2. Bajetić M, Uzelac Vidonja T. Raspoloživost, efikasnost i kvalitet lekova u pedijatriji, Arhiv za farmaciju 2012, 62: 279-87.
3. Krajnović D, Arsić J. Etička pitanja u pedijatrijskim kliničkim studijama: izazovi i problemi kod pacijenata sa retkim bolestima. JAHR 2014;10: 277-89.
4. Krajnović D. Etički i društveni aspekti u vezi sa retkim bolestima. U: Drezgic R, Radinković Ž, Krsitić P (ured.) Horizont bioetike: moral u doba tehničke reprodukcije života, Beograd: Univerzitet u Beogradu-Institut za filozofiju i društvenu teoriju 2012: 231-52.
5. Mandić I, Krajnović D. Talidomidska tragedija - lekcija iz prošlosti. Timočki medicinski glasnik 2009;34(2):126-34.
6. Riedel C, Lehmann B, Broich K, Sudhop T. Improving drug licensing for children and adolescents: position paper from the More Medicines for Minors Symposion 8 June 2015 in Bonn. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016; 59:S87–92.
7. Gočević CJ, Kauffman RE, Troendle GJ, Lambert GH. Is the’therapeutic orphan’ about to be adopted? Pediatrics. 1996; 98:118–23.
8. Rocchi F, Tomasi P. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zacchetti, Emilio Clementi, and Massimo Molteni. Pharmacol Res. 2011; 64:169–75.
9. Ufer M, Rane A, Karlsson Å, Kimland E, Bergman U. Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm. Eur J Clin Pharmacol. 2003; 58:779–83.
10. Nahata MC. New regulations for pediatric labeling of prescription drugs. Ann Pharmacother. 1996; 30:1032–3.
11. Suydam LA, Kubic MJ. FDA’s implementation of FDAMA: an interim balance sheet. Food Drug Law J. 2001; 56:131–5.
12. Ward RM, Kauffman R. Future of pediatric therapeutics: reauthorization of BPCA and PREA. Clin Pharmacol Ther. 2007; 81:477–9.
13. Fain K, Daubresse M. Alexander GC. The Food and Drug Administration Amendments Act and postmarketing commitments. JAMA. 2013; 310:202–4.
14. Hoppu K, Anahwani G, García-Bournissen F, Gazarian M, Kears GL, Nakamura H. et al. The status of paediatric medicines initiatives around the world—what has happened and what has not? Eur J Clin Pharmacol. 2012; 68:1–10.
15. Corny J, Lebel D, Bailey B. Bussières JF. Unlicensed and offlabel drug use in children before and after pediatric governmental initiatives. J Pediatr Pharmacol Ther. 2015; 20:316–28.
16. Dijkers, M. Introducing GRADE: a systematic approach to rating evidence in systematic reviews and to guideline development. KT Update (1). Austin, TX: SEDL Center on Knowledge Translation for Disability and Rehabilitation Research, 2013. Available from: http://www.ktdrr.org/products/update/v1n5/dijkers_grade_ktupdatev1n5.pdf
17. Bajetic M, Jelic-avic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R. et al. Off label and unlicensed drugs use in paediatric cardiology, Eur J Clin Pharmacol 2005; 61: 775–9.
18. Jong G.W. T, Eland IA, Sturkenboom M.C,J,M,van den Anker J.N, Stricker B.H.C. Unlicensed and offlabel prescription of respiratory drugs to children, Eur Respir J 2004; 23: 310–3.
19. Baiardi I P, Ceci A, Felisi M, Cantarutti L, Girotto S, Sturkenboom M. et al. In-label and off-label use of respiratory drugs in the Italian paediatric population, Acta Paediatrica 2010; 99: 544–9.
20. Conroy S, Pedon V. Unlicensed and off label analgesic use in paediatric pain management, Paediatric Anaesthesia 2001, 11: 431–6.
21. Moraes-Almeida, M., & Cabral, A, J. Off-label prescribing for allergic diseases in pre-school children. Allergologia et Immunopathologia 2014; 42(4): 342-4. doi:10.1016/j.alr.2013.02.011
1. Goločorbin-Ron S. i dr. Lekovi u prometu 2014. Novi Sad: OrtoMedics.
2. Bačetić M, Uzelac Vidonja T. Raspoloživost, efikasnost i kvalitet lekova u pedijatriji, Arhiv za farmaciju 2012, 62:279-87.
3. Krajnović D, Arsić J. Etička pitanja u pedijatrijskim kliničkim studijama: izazovi i problemi kod pacijenata sa retkim bolestima. JAHR 2014; 10: 277-89.
4. Krajnović D. Etički i društveni aspekti u vezi sa retkim bolestima. U: Drezgić R, Radinković Ž, Kristić P (ured.) Horizont bioetike: moral u doba tehnike reprodukcije života, Beograd: Univerzitet u Beogradu-Instistit za filozofiju i društvenu teoriju 2012:231-52.
5. Mandić I. Krajnović D: Talidomidska tragedija - lekcija iz prošlosti. Timočki medicinski glasnik 2009;34(2):126-34.
6. Riedel C, Lehmann B, Broich K, Sudhop T. Improving drug licensing for children and adolescents: position paper from the More Medicines for Minors Symposium 8 June 2015 in Bonn. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016; 59:1587-92.
7. Coté CJ, Kauffman RE, Troendle GJ, Lambert GH. Is the "therapeutic orphan" about to be adopted? Pediatrics. 1996; 98:118-23.
8. Rocchi F, Tomasi P. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmaco1 Res. 2011; 64:169-75.
9. Ufer M, Rane A, Karlsson Å, Kimland E, Bergman U. Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm. Eur J Clin Pharmacol. 2003; 58:779-83.
10. Nahata MC. New regulations for pediatric labeling of prescription drugs. Ann Pharmacother. 1996; 30:1032-3.
11. Suydam LA, Kubic MJ. FDA’s implementation of FDAMA: an interim balance sheet. Food Drug Law J. 2001; 56:131-5.
12. Ward RM, Kauffman R. Future of pediatric therapeutics: reauthorization of BPCA and PREA. Clin Pharmacol Ther. 2007; 81:477-9.
13. Fain K, Daubresse M, Alexander GC. The Food and Drug Administration Amendments Act and postmarketing commitments. JAMA. 2013; 310:202-4.
14. Hoppu K, Anabwani G, Garcia-Bournissen F, Gazarian M, Kearns GL, Nakamura H. et al. The status of paediatric medicines initiatives around the world—what has happened and what has not? Eur J Clin Pharmacol. 2012; 68:1-10.
15. Corny J, Lebel D, Bailey B, Bussières JF. Unlicensed and off-label drug use in children before and after pediatric governmental initiatives. J Pediatr Pharmacol Ther. 2015; 20:316-28.
16. Dijkers, M. Introducing GRADE: a systematic approach to rating evidence in systematic reviews and to guideline development. KT Update (1)5. Austin, TX: SEDL, Center on Knowledge Translation for Disability and Rehabilitation Research, 2013. Available from: http://www.ktdrr.org/products/update/v1n5/dijkers_grade_ktupdatev1n5.pdf
17. Bajetic M, Jelicavic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R. et al. Off label and unlicensed drugs use in paediatric cardiology, Eur J Clin Pharmacol 2005; 61:775-9.
22. Silva D, Ansotegui I, Morais-Almeida M. Off-label prescribing for allergic diseases in children, World Allergy Organization Journal 2014; 7:4.

23. Porta A, Esposito S, Menson E, Spyridis N, Tsolia M, Sharland M. et al., Off-label antibiotic use in children in three European countries, Eur J Clin Pharmacol 2010; 66:919–27.

24. Dominique L, Off-label use of Anticancer Drugs, Lancet Oncol 2008; 9:1102-07.